BennuBio
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$1.5m | Series A | ||
* | $5.0m | Series B | |
* | N/A | - | |
Total Funding | €5.9m |
Recent News about BennuBio
EditBennuBio, Inc. is a medical device startup revolutionizing the field of flow cytometry by providing advanced instruments capable of analyzing large particles at unprecedented speeds. The company serves clients in the pharmaceutical, biotechnology, and medical research sectors, offering solutions that significantly enhance the analysis of cellular populations. BennuBio's flagship product, the Velocyt Large Particle Flow Cytometer, utilizes acoustic standing waves to generate parallel sample streams, allowing for the analysis of particles up to 300 micrometers in diameter. This technology delivers volumetric sample delivery rates 100 times faster and analysis rates 10 to 100 times faster than traditional flow cytometers, making it ideal for applications such as rare cell analysis, detection of cells in large dilute samples, and rapid analysis of diluted blood samples. BennuBio operates in the global medical device market, leveraging a business model that includes direct sales, partnerships, and grants. The company generates revenue through the sale of its innovative flow cytometry instruments and related services.
Keywords: flow cytometry, large particle analysis, medical device, pharmaceutical research, biotechnology, cellular populations, Velocyt, acoustic standing waves, rapid analysis, high throughput.